119 related articles for article (PubMed ID: 38217082)
1. Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia.
Gharial J; Guilcher G; Truong T; Shah R; Desai S; Rojas-Vasquez M; Kangarloo B; Lewis V
Pediatr Blood Cancer; 2024 Apr; 71(4):e30844. PubMed ID: 38217082
[TBL] [Abstract][Full Text] [Related]
2. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
3. Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
Lee SS; Jung SH; Do YR; Kim DS; Lee JH; Park HS; Moon JH; Yi JH; Park Y; Koh Y; Yhim HY; Choi Y; Mun YC; Lee WS; Lee S; Yang DH;
Yonsei Med J; 2020 Jun; 61(6):452-459. PubMed ID: 32469169
[TBL] [Abstract][Full Text] [Related]
4. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
[TBL] [Abstract][Full Text] [Related]
6. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
7. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
8. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.
Mustafa Ali M; Abounader DM; Rybicki LA; Yurch MA; Starn J; Ferraro C; Winslow V; Hamilton BK; Gerds AT; Liu H; Dean R; Hill BT; Pohlman B; Andresen S; Hanna R; Kalaycio M; Bolwell BJ; Majhail NS; Sobecks RM
Biol Blood Marrow Transplant; 2017 May; 23(5):776-781. PubMed ID: 28108271
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
11. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
Speziali C; Daly A; Abuhaleeqa M; Nitta J; Abou Mourad Y; Seftel MD; Paulson K
Leuk Lymphoma; 2019 Mar; 60(3):639-648. PubMed ID: 30160568
[TBL] [Abstract][Full Text] [Related]
13. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
14. Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT.
Swoboda R; Labopin M; Giebel S; Angelucci E; Arat M; Aljurf M; Sica S; Pavlu J; Socié G; Bernasconi P; Rigacci L; Tischer J; Risitano A; Rovira M; Saccardi R; Pioltelli P; Van Gorkom G; Vitek A; Savani BN; Spyridonidis A; Peric Z; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Mar; 57(3):399-406. PubMed ID: 35031709
[TBL] [Abstract][Full Text] [Related]
15. Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Banet A; Bazarbachi A; Labopin M; Stocker N; Duléry R; Malard F; Van de Wyngaert Z; Genthon A; Memoli M; Legrand O; Bonnin A; Ledraa T; Belhocine R; Sestili S; El-Cheikh J; Mohty M; Brissot E
Bone Marrow Transplant; 2023 Jan; 58(1):61-67. PubMed ID: 36224494
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
Yamada Y; Ikegawa S; Najima Y; Atsuta Y; Konuma R; Adachi H; Wada A; Kishida Y; Konishi T; Nagata A; Kaito S; Nagata R; Noguchi Y; Marumo A; Mukae J; Inamoto K; Toya T; Igarashi A; Kobayashi T; Sakamaki H; Ohashi K; Doki N
Int J Hematol; 2022 Feb; 115(2):244-254. PubMed ID: 34652634
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
[TBL] [Abstract][Full Text] [Related]
18. A Single-Center Experience With Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: A Modest Pitch for Non-Total Body Irradiation Conditioning Regimens.
Hamidieh AA; Eslami Shahre Babaki A; Rostami T; Kasaeian A; Koochakzadeh L; Sharifi Aliabadi L; Behfar M; Ghavamzadeh A
Exp Clin Transplant; 2019 Apr; 17(2):243-250. PubMed ID: 30295587
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.
Shin HC; Lee YJ; Moon JH; Lee SJ; Kang BW; Chae YS; Kim JG; Choi JY; Seo JW; Kim YK; Suh JS; Sohn SK
Korean J Intern Med; 2012 Mar; 27(1):72-83. PubMed ID: 22403503
[TBL] [Abstract][Full Text] [Related]
20. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Kharfan-Dabaja MA; Labopin M; Bazarbachi A; Socie G; Kroeger N; Blaise D; Veelken H; Bermudez A; Or R; Lioure B; Beelen D; Fegueux N; Hamladji RM; Nagler A; Mohty M
Leuk Res; 2015 Sep; 39(9):933-7. PubMed ID: 26003666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
